Clinical Research Directory
Browse clinical research sites, groups, and studies.
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Sponsor: Neurocrine Biosciences
Summary
This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.
Official title: A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
600
Start Date
2025-07-11
Completion Date
2031-12
Last Updated
2026-05-15
Healthy Volunteers
No
Conditions
Interventions
NBI-1117568
NBI-1117568 will be administered per schedule specified in the arm description.
Locations (55)
Neurocrine Clinical Site
Bryant, Arkansas, United States
Neurocrine Clinical Site
Little Rock, Arkansas, United States
Neurocrine Clinical Site
Chino, California, United States
Neurocrine Clinical Site
Culver City, California, United States
Neurocrine Clinical Site
Garden Grove, California, United States
Neurocrine Clinical Site
La Habra, California, United States
Neurocrine Clinical Site
Lemon Grove, California, United States
Neurocrine Clinical Site
Oceanside, California, United States
Neurocrine Clinical Site
Pico Rivera, California, United States
Neurocrine Clinical Site
Riverside, California, United States
Neurocrine Clinical Site
San Diego, California, United States
Neurocrine Clinical Site
Sherman, California, United States
Neurocrine Clinical Site
Torrance, California, United States
Neurocrine Clinical Site
West Hills, California, United States
Neurocrine Clinical Site
Atlantis, Florida, United States
Neurocrine Clinical Site
Aventura, Florida, United States
Neurocrine Clinical Site
Doral, Florida, United States
Neurocrine Clinical Site
Hollywood, Florida, United States
Neurocrine Clinical Site
Maitland, Florida, United States
Neurocrine Clinical Site
Miami, Florida, United States
Neurocrine Clinical Site
Miami Lakes, Florida, United States
Neurocrine Clinical Site
Tampa, Florida, United States
Neurocrine Clinical Site
West Palm Beach, Florida, United States
Neurocrine Clinical Site
Atlanta, Georgia, United States
Neurocrine Clinical Site
Atlanta, Georgia, United States
Neurocrine Clinical Site
Decatur, Georgia, United States
Neurocrine Clinical Sites
Peachtree Corners, Georgia, United States
Neurocrine Clinical Site
Chicago, Illinois, United States
Neurocrine Clinical Site
Gaithersburg, Maryland, United States
Neurocrine Clinical Site
Boston, Massachusetts, United States
Neurocrine Clinical Site
Watertown, Massachusetts, United States
Neurocrine Clinical Site
Flowood, Mississippi, United States
Neurocrine Clinical Site
St Louis, Missouri, United States
Neurocrine Clinical Site
Marlton, New Jersey, United States
Neurocrine Clinical Site
Cedarhurst, New York, United States
Neurocrine Clinical Site
New York, New York, United States
Neurocrine Clinical Site
New York, New York, United States
Neurocrine Clincial Site
Staten Island, New York, United States
Neurocrine Clinical Sites
The Bronx, New York, United States
Neurocrine Clinical Sites
North Canton, Ohio, United States
Neurocrine Clinical Site
Philadelphia, Pennsylvania, United States
Neurocrine Clinical Site
Austin, Texas, United States
Neurocrine Clinical Site
DeSoto, Texas, United States
Neurocrine Clinical Site
Houston, Texas, United States
Neurocrine Clinical Sites
Orem, Utah, United States
Neurocrine Clinical Site
Orem, Utah, United States
Neurocrine Clinical Site
Bellevue, Washington, United States
Neurocrine Clinical Site
Veliko Tarnovo, Bulgaria
Neurocrine Clinical Site
Vratsa, Bulgaria
Neurocrine Clinical Site
Brasov, Romania
Neurocrine Clinical Site
Bucharest, Romania
Neurocrine Clinical Site
Sânpetru, Romania
Neurocrine Clinical Site
Belgrade, Serbia
Neurocrine Clinical Site
Gornja Toponica, Serbia
Neurocrine Clinical Site
Kragujevac, Serbia